ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 2019; Provides Consolidated Earnings Guidance for the Year Ending March 2020
The company provided consolidated earnings guidance for the year ending March 2020. For the year, the company expects net sales of JPY 53,000 million, operating income of JPY 2,000 million, and profit attributable to owners of parent of JPY 1,000 million.